Market Signal Briefing

Readers are advised to review the "Non-GAAP and Other Financial Measures" section of this press release for information regarding the presentation of financial measures that do not have standardized meaning under IFRS ® Accounting Standards. Readers are also advised to review the "Forward-Looking Information" section in this press release for information regarding certain forward-looking information and forward-looking statements contained in this press release.

Strategy appears to have purchased more than 4,000 bitcoin on Thursday, according to estimates derived from real-time trading data and community tracking dashboards monitoring the firm’s preferred equity sales.

Data from STRC.live and market trackers suggests the purchases were funded through heavy issuance of the company’s Variable Rate Series A Preferred Stock (STRC), a perpetual preferred instrument that Strategy has increasingly used to raise capital for bitcoin accumulation.

By end of day in New York, trading activity implied the firm had already raised enough capital to acquire more than 4,000 BTC, marking the largest single-day bitcoin purchase funded through STRC since the instrument launched.

The surge follows unusually strong activity earlier in the week. On March 10, STRC recorded a record $409 million in daily trading volume while maintaining roughly 3% 30-day volatility and a one-month volume-weighted average price near $99.78.

On-chain indicators and community monitoring suggested that day’s activity funded the purchase of more than 2,000 BTC, already one of the largest one-day accumulations tied to the instrument.

Thursday’s pace easily surpassed that figure.

Strategy, already the largest public corporate holder of bitcoin, has increasingly leaned on its preferred equity program to finance additional acquisitions.

Earlier this year the company amended its at-the-market (ATM) program, allowing multiple agents to sell STRC shares simultaneously. The change increased liquidity in the instrument and made it easier for Strategy to raise large amounts of capital quickly, with proceeds directed toward bitcoin purchases.

Real-time dashboards tracking STRC trading attempt to estimate how many shares Strategy itself is issuing versus secondary market trades. 

Because the company previously indicated it may sell shares when the price trades above its $100 stated amount, analysts can approximate capital raised when trading occurs above that threshold.

A recent SEC filing disclosed that the company purchased 17,994 BTC between March 2 and March 8 for approximately $1.28 billion. That acquisition lifted the firm’s total holdings to about 738,731 BTC, representing roughly 3.5% of bitcoin’s circulating supply.

The filing showed the purchase was funded through a combination of $377.1 million in STRC sales and $899.5 million raised through common stock issuance.

Based on those figures, STRC accounted for about 29.5% of the funding for that five-day accumulation period, equivalent to roughly 5,300 BTC acquired through preferred share sales.

If Thursday’s estimates prove accurate, the day’s purchases alone could exceed the average daily bitcoin acquisition pace seen during that earlier buying window.

The data remains unofficial. Strategy typically confirms purchases later through SEC filings or public disclosures.

BREAKING: Michael Saylor's Strategy is now estimated to have accumulated 4,038 BTC today via STRC 🤯

Nearly double it's previous daily record! 🚀

pic.twitter.com/aFzTtwIE2R

— Bitcoin Magazine (@BitcoinMagazine) March 12, 2026 How does Strategy’s STRC work? STRC acts as a bridge between traditional income investors and Strategy’s Bitcoin-focused balance sheet. Income investors typically seek steady payouts, while Strategy’s large Bitcoin holdings bring long-term upside along with short-term price swings. The preferred stock helps connect these two profiles.

The security is structured to keep demand near its $100 par value while paying a monthly dividend that yields about 11.5% annually. In effect, it converts the economics of a Bitcoin treasury into a format that appeals to fixed-income investors who prioritize regular income.

Strong liquidity and relatively low volatility suggest that the investor base is shifting toward income-focused capital. That shift can help stabilize trading activity compared with instruments driven mainly by speculation.

These early results point to product-market fit. Rather than relying on marketing or hype, the structure appears to meet a clear demand among investors seeking yield tied to Bitcoin exposure.

For corporate leaders considering Bitcoin treasury strategies, STRC offers a way to integrate Bitcoin into broader capital structures. It allows companies to draw funding from multiple investor groups while building a shared strategic reserve around the asset.

At the time of writing, Bitcoin trades near $70,000, while shares of MicroStrategy (MSTR) are down about 0.75% on the day.

Micah Zimmerman

Micah first discovered Bitcoin in 2018 but remained a skeptic on the sidelines for too long. Since 2021, he has covered crypto and business and now works as a news reporter for Bitcoin Magazine, based in North Carolina.

Just when the TRUMP meme coin looked like it had fallen off a financial cliff, its promoters pulled out the old crypto playbook: throw another gala, invite the faithful, and hope the price chart stops screaming. From $74 to $2.

📊
No votes yet – Be the first to vote

Bitcoin funding rates went negative. Traders betting against the crypto are now paying fees to maintain their short positions, a clear sign that bearish sentiment has taken hold across the market.

The shift happened March 12, 2026, when perpetual futures funding rates flipped into negative territory for the first time in months. Funding rates represent periodic payments between long and short position holders in futures contracts. When rates turn negative, it means shorts pay longs – basically, pessimistic traders are so convinced Bitcoin will drop that they’re willing to pay extra to keep their bets active. Geopolitical tensions and weak labor data have traders spooked. The mood feels pretty grim right now.

Market watchers can’t ignore the obvious.

But here’s where things get interesting – institutional buyers are still scooping up Bitcoin below $75,000. Major players seem to think current prices offer value, even while funding rates scream bearish. Some analysts believe this institutional buying could eventually dry up the selling pressure. Maybe that triggers the next bull run. Nobody knows for sure yet.

The Chicago Mercantile Exchange reported March 10 that open interest for Bitcoin futures jumped significantly. More traders are piling into the market, either hedging against further drops or betting on more pain ahead. CME’s data shows engagement is actually growing despite the negative funding environment.

Short sellers aren’t backing down.

Their confidence appears to be building. These traders keep paying funding fees because they believe Bitcoin’s price will fall further. That’s basically putting money where their mouth is. The willingness to pay these premiums tells you everything about current market psychology.

Glassnode saw major Bitcoin outflows from exchanges March 11. Coins are moving to private wallets, which could mean some investors are preparing to hold long-term despite the bearish vibes. Crypto analyst Sarah Thompson thinks the negative funding rates might actually discourage new long positions. She said traders are being extra cautious about potential losses right now. This follows earlier reporting on Bitcoin Futures Hit Five Times Spot.

Bitcoin’s price hovers around $72,000 with wild swings expected. The crypto community is watching every tick, looking for signs that funding rates might shift or trading volumes could signal a direction change. Major exchanges haven’t commented on the funding rate trend, which adds to the uncertainty.

Binance reported a 15% jump in trading volumes March 11, driven mostly by retail investors trying to catch potential rebounds. Small traders seem more opportunistic than institutional players. They’re basically gambling that current prices represent a bottom. Retail and institutional approaches couldn’t be more different right now.

CryptoQuant found that Bitcoin addresses holding significant amounts increased 4% over the past week. Some investors are still accumulating despite negative funding rates. They’re probably betting on future price recovery, but that’s a risky game when shorts are paying premiums to stay bearish.

JP Morgan warned clients March 10 to stay cautious, citing potential volatility from current funding dynamics. The bank is closely monitoring how crypto markets respond to broader economic changes. Their guidance reflects the heightened uncertainty that’s gripping everyone from Wall Street to crypto Twitter.

Coinbase and Kraken both reported steady volumes March 12. Trading activity remains robust even though sentiment has turned sour. Bitcoin is still the main focus for traders trying to navigate these choppy waters. Volume doesn’t lie – people are still actively trading despite the negative funding environment.

The situation changes fast in crypto. Traders are navigating a landscape filled with mixed signals and conflicting data points. Institutional buying versus retail speculation. Negative funding rates versus steady volumes. Nobody really knows which force will win out. For more details, see Bitcoin Stalls Near K as Fed.

Market participants are watching funding rate changes like hawks. These rates serve as a real-time sentiment gauge, giving insights into where prices might head next. If negative rates persist, it could reshape trading strategies across the board. Some traders might avoid long positions entirely until sentiment shifts.

The timeline for any potential turnaround remains murky. Institutional investors’ next moves will be crucial, along with how short sellers react to any price bounces. Until then, speculation runs wild and the crypto market watches every development closely.

A bull run might still be coming. But nobody can predict when or how intense it’ll be. The lack of clear indicators keeps everyone guessing. Efforts to get comments from major exchanges have been unsuccessful so far.

The negative funding rates mirror similar patterns seen during Bitcoin’s major corrections in 2022 and 2018. During those periods, sustained negative rates preceded significant price movements, though predicting the exact direction proved nearly impossible. Derivatives markets often amplify underlying sentiment, creating feedback loops that can accelerate both crashes and recoveries.

Meanwhile, regulatory developments in Europe and Asia are adding another layer of complexity to trader decisions. The European Central Bank’s recent statements about digital asset oversight have some institutional players reassessing their crypto allocations. Asian markets, particularly South Korea and Japan, are seeing increased regulatory scrutiny that could influence global Bitcoin flows in the coming weeks.

Post Views: 4

A new analysis from crypto analytics platform CoinCodex paints a grim picture for Shiba Inu (SHIB) investors who are still holding out hope for a repeat of past highs this year. According to the AI platform, SHIB is highly unlikely to approach, let alone reach its 2021 all-time high in 2026. The dog-themed meme coin has been volatile, with analysts indicating that its broader outlook remains largely bearish.

CoinCodex’s recent price forecast for Shiba Inu offers little optimism for the popular meme coin in the near term. The AI algorithm, which factors in historical price behavior, market volatility, and Bitcoin halving cycles, concludes that SHIB has no realistic path to regaining its all-time high in 2026.

Shiba Inu Unlikely To Reach ATH In 2026 Notably, Shiba Inu hit an ATH of approximately $0.000088 in 2021, a level it has failed to revisit in years. As of March 12, 2026, the meme coin trades around $0.0000058, which puts it more than 93% below that historic peak. Closing that gap would require a staggering price rally of roughly 1,400%, which is about 15x its current price. 

Related Reading: Shiba Inu Whales Are On The Move Again, But In What Direction?

CoinCodex notes that the broader market picture for SHIB is broadly negative across almost every key metric. Currently, sentiment is 71% bearish and 29% bullish, and the Fear and Greed Index sits at 15, placing the market in extreme fear territory.

Source: Chart from CoinCodex In the past 30 days, SHIB has closed green only 11 times, meaning it posted gains on just 37% of trading days. Volatility is also elevated at 6.8%, reflecting sharp price swings without any sustained upward direction. Additionally, technical indicators are stacking up heavily on the bearish side, with CoinCodex showing 20 sell signals for Shiba Inu compared to just 8 buy signals. 

Furthermore, SHIB’s 50-day Simple Moving Average (SMA) sits at $0.0000065, and the 200-day SMA at $0.0000093, both well above the current price and equally pointing toward continued selling pressure. CoinCodex also highlights that Shiba Inu’s 14-day Relative Strength Index (RSI) currently reads at 42.89, landing in neutral territory but trending toward the lower end of the scale. Alongside the moving averages, this reading illustrates a glaring weakness in momentum with no clear signal that buyers are ready to step in and push prices toward ATH levels. 

CoinCodex Reveals Long Road Ahead For SHIB CoinCodex’s short-term projections offer modest upside from current levels, with the one-month forecast showing a potential gain of around 6.76% to $0.0000061. However, that mild optimism fades quickly, as the AI model projects SHIB could end 2026 below where it trades today. 

The longer-term outlook also does little to encourage investors and holders. Any meaningful price recovery is not expected to happen until well into the 2040s, and even the most optimistic long-range forecast still falls short of the 2021 all-time high. 

Adding to this lackluster outlook, CoinCodex notes that Shiba Inu’s support and resistance levels are compressed into a very tight range, suggesting that the market has little room for a breakout in either direction. For now, SHIB remains range-bound, with no evident short-term catalyst strong enough to propel it back to its historic peak.

SHIB trading at $0.0000058 on the 1D chart | Source: DOGEUSDT on Tradingview.com Featured image from Adobe Stock, chart from Tradingview.com

TL;DR:

Kraken Momentum: The price of PI surpassed $0.25, a 10% increase, after its upcoming listing on the Kraken exchange was officially confirmed. Explosive Metrics: Buying volume doubled to $89.4 million (a 112% rise), recovering 80% from February lows. Technical Support: The asset is consolidating above the 200-day moving average ($0.22), while the market anticipates the v20.2 protocol update. Pi Network shook the crypto market by reaching a new yearly high, driven by massive organic demand and validation from major institutional platforms. This trend suggests that a potential all-time record price could be the next target if the current support zone remains firm.

From a technical perspective, PI managed to break the intermediate resistance at $0.24, turning it into a solid operational base. The Relative Strength Index (RSI) has entered overbought territory, indicating predominant bullish strength, although a cooling-off phase is not ruled out before attacking the critical resistance at $0.28.

Improvements in the network’s infrastructure have renewed investor confidence. In particular, expectations surrounding protocol version 20.2 have prepared the ecosystem for an increase in transactional volume.

Consequently, the move above the 200-day moving average is a signal of a long-term trend reversal. This indicator, located near $0.22, now acts as the main containment wall against any bearish correction.

Projections: The Path to $0.32 In line with this optimism, if the PI price manages to consolidate the $0.25 level as structural support, the next technical objective will be to reach $0.28. A sustained breakout of this mark would open the doors to explore the range between $0.30 and $0.32 in the short term.

In summary, Pi Network is currently the protagonist of a market turnaround, rebounding 80% from its lowest levels. The combination of solid fundamentals, such as the Kraken listing, and a bullish technical structure, positions the asset on a trajectory of sustained growth toward new horizons.

BlackRock’s staked Ethereum exchange-traded fund has tallied $15.5 million in trading volume on its first trading day, which a market analyst described as “very, very solid” despite falling short of two similar Solana staking products that launched last year.

Nasdaq data shows the iShares Staked Ethereum Trust (ETHB) had 592,804 shares traded on its debut on Thursday, with Bloomberg ETF analyst James Seyffart noting on X that the product turned over around $15.5 million.

“Very, very solid for a day 1 ETF launch,” Seyffart said.

The ETF invests and stakes Ether (ETH), locking up the tokens on the blockchain with the aim of providing a yield. The fund relies on network validators to capture staking rewards, typically offering a yield of 4% annually.

Source: James Seyffart
ETHB’s $15.5 million in debut trading volume trailed similar staking funds tied to the Solana (SOL) token, including the $55.4 million in volume recorded by the Bitwise Solana Staking ETF (BSOL) when it debuted in October. Another similar fund, the REX-Osprey SOL + Staking ETF (SSK), also recorded $33.7 million on its debut in July.

ETHB adds to BlackRock’s crypto product lineup, which includes its two flagship crypto funds, the iShares Bitcoin Trust ETF (IBIT) and iShares Ethereum Trust ETF (ETHA). 

The two ETFs have respectively attracted over $62.8 billion and $11.9 billion worth of inflows since launching in 2024, Farside Investors data shows.

BlackRock is also looking to offer a Bitcoin Premium Income ETF, which would sell covered call options on Bitcoin futures, collecting premiums to generate yield. 

ETHB is backed by 80% staked Ether and 20% Ether, according to BlackRock’s website. It launched with $106.7 million in net assets, which is being custodied by Coinbase.

Staking rewards will be distributed on a monthly basis and will be obtained from Ethereum network validators run by Figment, Galaxy Digital and Bitwise-owned Attestant.

ETHB offers a 0.25% sponsor fee with a one-year waiver, reducing the fee to 0.12% on the first $2.5 billion assets under management.

Magazine: What’s a ‘Network State’ and are there real-life examples? Big Questions

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

A crypto trader ignored all warnings and risks when they swapped $50 million in Tether for AAVE, only to end up with $36,000. In a post on X, Aave founder Stani Kulechov said the trader ignored all price-impact warnings and confirmed the transaction on a smartphone despite the risks.

Decentralized platforms use liquidity pools of tokens, and when someone tries to buy a very large amount at once, the system starts using the available tokens, gradually raising the price as they are exhausted. For this reason, a trader may end up with fewer tokens than expected at the end of the trade as each next token the system uses becomes more expensive. 

In this case, the trader on Aave saw their buying power weaken, and the cost of each token rose sharply because the liquidity pool lacked enough tokens to cover the $50 million order. So out of the millions invested, the trader received only about 324 AAVE tokens (roughly $36,000 at market prices).

A large trade caused massive slippage This event explains why big trades occur smoothly with ample liquidity, whereas prices rise quickly and traders lose money with limited liquidity. Similarly, decentralized systems won’t end a trade automatically just because prices rise astronomically or send big orders to special traders with better prices. 

The trading platform CoW Swap later confirmed that there weren’t any issues with the system and that the trade went as expected, as the rules state that a trade cannot be undone once signed and confirmed on the blockchain.

The news of the trader’s loss spread across social media, and users began sharing their thoughts, worries, and frustrations about the issue, questioning whether platforms like AAve should allow extremely large swaps in the first place.

Comments under Stani Kulechov’s post on X claimed that many users still don’t fully understand how serious the risks can be, given technical terms like slippage or liquidity depth, so warning messages before transactions carry less weight. 

Some users suggested that platforms block swaps with slippage above certain thresholds to prevent users from accidentally approving risky trades, while others said protocols should give traders more time to think by implementing multiple confirmation steps. 

Additionally, some traders said platforms should split very large swaps into smaller pieces or route them through sources with deeper liquidity to reduce sudden price jumps. 

DeFi debate intensifies as trader loss highlights risks The opposition takes a different view, as users who support open systems argue that the whole point of DeFi is to give users full control over their money and decisions. So if platforms start implementing restrictions, the systems will start feeling like traditional finance, where middlemen make all the decisions on behalf of users. 

While the two sides argued, critics asked questions about the missing value in the trade, saying slippage doesn’t mean money disappears into thin air but rather distributes value across the system. 

They explained that liquidity providers and arbitrage traders benefit from the loss, which dismisses the idea that it was a hack or technical failure.

Aave founder Stani Kulechov said the team is trying to reach out to the affected trader and return about $600,000 in fees collected during the swap, but they cannot reverse the main transaction because blockchain settlements are final.

Kulechov presented ideas for better safety nets, such as improved warning mechanisms that display actual execution results, optimized routing strategies that seek deeper liquidity before executing a trade, and enhanced analytics to provide better visibility into the price impact of trades.

This episode demonstrates the benefits of decentralized finance, which allows users to cut out the middleman and take control of their own assets. However, the flip side is that many of the safety nets that users are accustomed to are eliminated. When errors are made, the results are immediate, take only seconds, and are irreversible.

The crypto token Avanatis [AVNT] outperformed the entire crypto market as it surged over 24% in the last 24 hours. The market cap of the entire sector only rose by 0.48% as the Fear & Greed Index jumped from “extreme fear” to 26 as of press time.

In fact, the spike in price action was reflected in the daily trading volume that jumped by 528%, as per CoinMarketCap.

This indicated growth in trading activity, which was fueled by fundamental news and supply dynamics, which likely contributed to increased investor interest.

Why Avantis’ price rallied in the past 24 hours According to Avantis on X, they were embarking on reducing the token supply. To achieve this, they would be using 30% of the daily trading fees generated to buy AVNT from the open market and permanently burning them.

In fact, this systematic buy-back and burn mechanism was rolled out immediately, with the second milestone targeting a 50% burn of the fees. This would accelerate tightening the supply of AVNT tokens, whose maximum supply stood at 1 billion, while the circulating supply was at 319 million tokens.

As per the Avantis Foundation website, the total burned tokens had already reached 57,324 AVNT, worth about $9,167. The highest number was burned on March 11th, which represented half of this total, 28,981 AVNT valued at $4,607.

Source: Avantis Foundation This action elicited sentiment across the social networks, which ballooned after another exchange listing. Uphold announced that they had listed the AVNT token to be traded exclusively in the next 24 hours.

Such a listing meant liquidity expansion and more reach. The strength was evident on the price action charts.

AVNT price breaks out of descending channel The 4-hour chart showed AVNT had broken out from the one-and-a-half-month consolidation inside a falling trend channel.

The price action paused after briefly surpassing the $0.20 zone, which was a strong short-term resistance. However, staying above this level could push AVNT toward $0.22.

The spike in sentiment was reflected on the charts as the reading jumped to 100%. Also, the token volume was buyer dominant, with the Cumulative Volume Delta (CVD) spiking to 5.6 million AVNT in the past 24 hours.

Source: AVNT/USDT on TradingView However, the CVD dropped to negative 287K AVNT tokens indicated selling pressure was kicking in, probably from the profit-taking. That could be problematic for the current short-term bullish trend, as it suggests that the selling pressure may lead to a reversal in price momentum.

Liquidations spike in 12 hours The total liquidations on Avantis were at $616K, with shorts accounting for $316K while longs were $299K. The biggest liquidations happened on Binance, followed by OKX and Bybit.

Source: CoinGlass Therefore, liquidations amplified the gains, but they pointed out that traders were closing their positions.

Final Summary Avantis rallies 24% following its Uphold listing and the launch of a buy-back and burn mechanism.  AVNT price broke out of a descending trend channel, but traders were starting to take profit, as the CVD showed. 

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Bitcoin has spent the past two weeks in a war zone; not literally, but functionally. Since US and Israeli forces launched coordinated strikes on Iran on February 28, crypto markets have been held hostage by geopolitical shock, energy price chaos, and a global risk-off mood that has kept institutional conviction firmly on the sidelines.

Now, with Trump signaling he wants the conflict over soon, what happens to Bitcoin? The answer is based on current on-chain data and market structure, and ETF flows, for instance, are already leaning positively.

Bitcoin Trading Under A Geopolitical Discount Bitcoin was already showing signs of a market that had been beaten down but not broken before a single missile was fired. On-and-off tensions in the Middle East have had broad consequences across global markets, and Bitcoin was not immune to these pressures. 

Bitcoin hit $74,000 in early March before pulling back as news of Iranian counter-strikes rattled investor sentiment. That price level is now the most important level the market needs to reclaim, and the tensions are the primary obstacle standing in the way.

However, according to the report from Glassnode, the leading cryptocurrency has begun to recover for the larger part of its metrics. Momentum has begun to recover, and the RSI has lifted from recent lows, but price action is still looking for the strength of a decisive bullish move. Still, the realized profit-to-loss ratio, supply in profit, and net unrealized profit and loss (NUPL) are all posting modest improvements.

Source: Chart from Glassnode on X Can The Bitcoin Price Surge Soon? The war’s most consequential macroeconomic effect has been on energy prices. The price for a barrel of Brent crude surged to $119.50 per barrel as the conflict intensified, with markets panicking above $100. A resolution to the conflict would likely ease several of the forces currently weighing on global markets. This, in turn, is expected to lead to a stabilization of oil prices. 

Bitcoin tends to respond positively when macro conditions become more supportive of risk assets. Glassnode’s derivatives data shows that traders have already begun positioning for a possible recovery through improving profitability metrics, rising derivatives engagement, and persistent ETF inflows. 

Futures open interest rose 5.1% to $29.4 billion, while perpetual CVD surged 201.7% to $172.6 million, which is a sign of strong buy-side activity in perpetual futures markets.

Options markets are also showing signs of a less defensive outlook. Options open interest climbed from $32.8 billion to $34.1 billion, while the volatility spread narrowed and the 25-delta skew has started declining.

ETF demand could also add to the next Bitcoin rally as the main source of demand. Glassnode reported that weekly net inflows into US Spot Bitcoin ETFs rose from $776 million to $934 million, while ETF trading volumes increased from $16.0 billion to $23.1 billion. 

Interestingly, data from SoSoValue shows that these Spot Bitcoin ETFs have now seen three days of consecutive inflows at the time of writing.

BTC trading at $70,438 on the 1D chart | Source: BTCUSDT on Tradingview.com Featured image from Pixabay, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Corporate finance teams are beginning to view digital assets and stablecoins as practical tools for treasury management, vendor payments, and payroll, signaling a potential shift as Ripple leadership points to CFO offices as drivers of the next phase of blockchain adoption.

Altcoin News

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Ahmed Balaha

Author

Ahmed Balaha

Part of the Team Since

Aug 2025

About Author

Ahmed Balaha is a journalist and copywriter based in Georgia with a growing focus on blockchain technology, DeFi, AI, privacy, digital assets, and fintech innovation.

Has Also Written

Fact Checked by

CryptoNews Editorial Team

Author

CryptoNews Editorial Team

Part of the Team Since

Sep 2018

About Author

The CryptoNews editorial team is composed of seasoned writers specializing in cryptocurrency and blockchain technology. Their expertise ensures comprehensive, accurate, and insightful content for...

Has Also Written

Ad Disclosure

Ad Disclosure

We believe in full transparency with our readers. Some of our content includes affiliate links, and we may earn a commission through these partnerships. However, this potential compensation never influences our analysis, opinions, or reviews. Our editorial content is created independently of our marketing partnerships, and our ratings are based solely on our established evaluation criteria. Read More

Last updated: 

2 minutes ago

When a $500 billion payments giant puts your name on the list, you pay attention.

Mastercard just launched its Crypto Partner Program, a global initiative pulling together more than 85 companies from across crypto, payments, and fintech.

Solana is on that list. So are PayPal, Binance, Ripple, Circle, Gemini, and Paxos. Those names constitute the infrastructure layer of the entire digital asset economy, all sitting inside one program.

Visa currently processes around 90% of all crypto-linked card payment volume, largely because it moved first.

Mastercard is playing catch-up, and this program is how it closes that gap. The Crypto Partner Program creates a direct collaboration channel between blockchain developers, financial institutions, and payment providers, with the goal of making digital assets work within the systems people already use every day.

Participants work directly with Mastercard teams to build products that combine the speed and programmability of blockchains with existing card networks and global commerce infrastructure. The real-world proof-of-concept is already running.

Kazakhstan’s central bank launched a tenge-pegged stablecoin built on Solana, and Mastercard is moving to enable it for card payments inside the country’s regulatory sandbox.

Stablecoin settlement for card transactions and self-custodied wallet payment cards are already being tested across the ecosystem. This is not theoretical anymore.

Solana Price Prediction: Is SOL About to Explode?SOL is sitting at $86 at the time of writing, and for a coin that is becoming the backbone of crypto, the chart looks like the market has not caught up to that reality yet.

Price has been building higher lows inside a rising wedge since the February bottom. The most recent move saw price push up and get rejected hard at $92, which is now the key resistance level standing between SOL and the real targets above.

Source: SOLUSD / TradingViewThat rejection sent price back into consolidation, and the dotted path on the chart shows the risk of a deeper flush toward $80 or $75 before the next leg higher, with $70 sitting as the last serious floor if things get ugly.

A clean break and hold above $92 changes everything, opening the ladder toward $106 first and then the full $120 target.

Maxi Doge Targets Early Mover Upside as Solana Tests Key LevelsSolana is stuck defending $80 with $59 lurking below. Not exactly inspiring confidence.

And that is the thing about large caps. Solid? Sure. But the market cap is already massive. The 100x run is basically off the table.

So attention shifts. Traders hunting bigger multiples are landing on plays like Maxi Doge. A new ERC-20 meme coin built around high-energy trading culture and the kind of upside large caps simply cannot offer anymore.

The whole energy is built around that 1000x mentality. And early numbers show it is landing. $4.6M raised in the presale already.

$MAXI is currently priced at $0.0002808 and is not shy about what it is. The self-proclaimed Leverage King. Gym-bro marketing, holder-only trading competitions, and a dynamic staking system keep the community locked in.

“Never skip leg day, never skip a pump.”

The Treasury fund backs it all, rewarding active holders and aiming to outlast established meme coins through pure community momentum.

For those hedging against Solana’s short-term volatility, this early-entry opportunity offers a distinct risk-reward profile compared to established altcoins.

Visit the Official Maxi Doge Website Here

Solana is attempting to stabilize after recent downside pressure, with the $85 level emerging as a key support zone. Price action is beginning to show early signs of base formation as bulls try to defend this area and slow the broader decline. While the short-term structure hints at a possible recovery attempt, a stronger shift in momentum will likely require a decisive push toward higher resistance levels.

Solana Shows Early Signs Of Stabilization Near Key Zone In a recent technical brief, MakroVision Research highlighted that Solana is beginning to display early signs of stabilization following its recent period of weakness. While the broader market structure remains under pressure, current price behavior suggests selling momentum may be slowing, allowing the market to attempt a short-term recovery phase.

According to the analysis, Solana is presently consolidating just above the $85 level, a price zone that carries significant short-term importance. At the same time, the chart is forming a slightly rising structure characterized by gradually higher lows. As this pattern develops, the price is once again approaching the upper boundary of the formation, suggesting that market participants are testing whether enough momentum exists to push the price higher.

Source: Chart from MakroVision Research on X Despite these constructive short-term developments, the broader trend remains bearish. Solana is still trading clearly below the descending red trendline, which continues to confirm the prevailing downtrend.

$100 Trendline Break Could Signal Bullish Shift The analyst further stressed that a clear breakout above the descending red trendline around the $100 level would represent the first meaningful bullish signal for Solana in the current market structure. This suggests that buyers are beginning to regain control, potentially opening the door for a stronger recovery and a shift in short-term momentum.

On the other hand, the outlook remains cautious as long as the price continues to trade below that key trendline resistance. If Solana approaches the $100 area but faces another strong rejection, it would reinforce the idea that the broader downtrend remains firmly intact.

In the near term, Solana appears to be stabilizing after its recent decline and is attempting to build a potential base structure. The emergence of gradually rising lows suggests that buyers are starting to defend current levels, which could provide a foundation for a possible upward move if momentum improves.

For the bullish scenario to gain traction, holding the $85 support level remains crucial. As long as this zone continues to act as a floor, the market retains the possibility of pushing higher. A sustained reclaim of the $100 level would be the real turning point to improving the overall technical outlook, while repeated rejections would confirm the existing downtrend.

SOL trading at $86 on the 1D chart | Source: SOLUSDT on Tradingview.com Featured image from iStock, chart from Tradingview.com

Oil prices surged last week as geopolitical tensions in Iran and the surrounding regions continued to flare. In recent trading days, oil prices have reverted sharply, sliding from a temporary high of $115 per barrel on March 9 to around $80 per barrel today. Still, oil prices remain roughly 40% higher since the year began.

What do volatile, rising oil prices have to do with artificial intelligence (AI) stocks? There's a sneaky angle tech investors should be aware of.

Many AI data centers still rely on fossil fuels It's not just oil prices that are going up. Natural gas prices are also up more than 16% since the year began. That's a challenge when you consider that fossil fuels still supply data centers with around 60% of their power need per data from the International Energy Agency (IEA). Renewables supply around 27% of the required electricity, with nuclear contributing 15%.

Image source: Getty Images.

With fossil fuel prices on the rise -- or at least demonstrating high levels of volatility -- the global data center build-out to support the AI industry's rapidly growing compute needs now faces an additional hurdle. This is likely good news for companies like Oklo (OKLO 5.05%) and NuScale Power (SMR 5.01%), which are developing smaller, modular nuclear reactors that can help data centers relieve themselves of this price uncertainty. Oklo's business strategy is specifically geared toward supplying AI-focused data centers with reliable base load power that is largely sheltered from swings in fossil fuel prices.

Today's Change

(

-5.05

%) $

-3.17

Current Price

$

59.59

It's just another piece of the puzzle that could impact the scale and pace of the global data center build-out. But rising energy prices should put a greater spotlight on companies looking to supply this build-out with a clean, reliable, power supply with stable pricing.

Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool recommends NuScale Power. The Motley Fool has a disclosure policy.

Runway Growth Finance Corp. (RWAY) Q4 2025 Earnings Call March 12, 2026 5:00 PM EDT

Company Participants

Quinlan Abel - Assistant Vice President of Investor Relations
David Spreng - Founder, President, CEO & Director
Greg Greifeld - Chief Investment Officer
Thomas Raterman - CFO & Chief Operating officer

Conference Call Participants

Erik Zwick - Lucid Capital Markets, LLC, Research Division
Casey Alexander - Compass Point Research & Trading, LLC, Research Division
Richard Shane - JPMorgan Chase & Co, Research Division
Sean-Paul Adams - B. Riley Securities, Inc., Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Runway Growth Finance Fourth Quarter and Fiscal Year Ended 2025 Earnings Conference Call. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Quinlan Abel, Assistant Vice President, Investor Relations. Please go ahead.

Quinlan Abel
Assistant Vice President of Investor Relations

Thank you, operator. Good evening, everyone, and welcome to the Runway Growth Finance Conference Call for the Fourth Quarter and Fiscal Year ended December 31, 2025. Joining us on the call today from Runway Growth Finance are David Spreng, Chief Executive Officer; Greg Greifeld, Chief Investment Officer of Runway Growth Capital LLC, our investment adviser; and Tom Raterman, Chief Financial Officer and Chief Operating Officer.

Runway Growth Finance's fourth quarter and fiscal year ended 2025 financial results were released just after today's market close and can be accessed from Runway Growth Finance's Investor Relations website at investors.runwaygrowth.com. We have arranged for a replay of the call to be available on the Runway Growth Finance web page.

During this call, I want to remind you that we may make forward-looking statements based on current expectations. The statements on this call that are not purely historical are forward-looking statements. These forward-looking statements are not a guarantee

Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - Coloured Ties Capital Inc. (TSXV: TIE) (OTC Pink: APEOF) (FSE: 97A0) ("CTI" or the "Company") announces that this press release is being disseminated as required by National Instrument 62-103 The Early Warning System and Related Take Over Bids and Insider Reporting Issues, in connection with the filing of an early warning report (the "Early Warning Report") regarding CTI's acquisition of common shares of LaFleur Minerals Inc. (CSE: LFLR) ("LaFleur") (the "Common Shares") on June 5, 2025, and the reduction in ownership resulting from private placements conducted by LaFleur on September 10, 2025 and December 30, 2025.

CTI announces that on June 5, 2025, CTI acquired control and direction over 2,474,526 Common Shares in the capital of LaFleur. The 2,474,526 Common Shares were received by CTI from PricewaterhouseCoopers Inc. in its capacity as monitor of Beacon Gold Mill Inc. (the "Transaction"). Pursuant to the Transaction, the Common Shares were acquired at a price of $0.15 per Common Share for aggregate consideration of $371,178.90. Prior to the Transaction, CTI had control and direction over 17,363,711 Common Shares, representing approximately 27.34% of issued and outstanding Common Shares. Following completion of the Transaction, CTI has control and direction over 19,838,237 Common Shares, representing approximately 31.24% of the issued and outstanding Common Shares. As a result of the Transaction, CTI acquired 2,474,526 Common Shares, representing 3.9% of the issued and outstanding Common Shares on a non-diluted and partially diluted basis, as there are no warrants, options, or other convertible securities of LaFleur currently outstanding.

As a result of the private placement completed by LaFleur on September 10, 2025, CTI's ownership share of LaFleur was reduced from 31.76% to 29.03% of the issued and outstanding shares of LaFleur on a non-diluted and partially diluted basis, as there are no warrants, options, or other convertible securities of LaFleur currently outstanding.

As a result of the private placement and flow-through offering completed by LaFleur on December 30, 2025, CTI's ownership share of LaFleur was reduced from 28.39% to 24.18% of the issued and outstanding shares of LaFleur on a non-diluted and partially diluted basis, as there are no warrants, options, or other convertible securities of LaFleur currently outstanding.

The Common Shares were acquired for investment purposes. CTI may, depending on market and other conditions, increase or decrease their ownership of LaFleur's securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities.

This news release is being issued in accordance with National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. CTI has filed a corresponding Early Warning Report on its SEDAR+ profile which can be viewed at www.sedarplus.ca.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288369

Source: Coloured Ties Capital Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

March 12, 2026 21:03 ET  | Source: Eupraxia Pharmaceuticals Inc.

VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise.

“2025 was a pivotal year for Eupraxia. We achieved significant clinical milestones in the development of our lead program, EP-104GI, and strengthened our balance sheet with two recent financings, positioning us well for our next phase of growth” said James Helliwell, CEO of Eupraxia. “As we look ahead to an exciting year, we anticipate multiple clinical readouts from the ongoing RESOLVE trial and the initiation of additional clinical programs in new indications to further expand and strengthen our pipeline”

Recent Operational and Financial Highlights

On November 13, 2025, the Company announced additional 52-week follow-up data from the RESOLVE trial in eosinophilic esophagitis (“EoE”) demonstrating consistent results after dosing with EP-104GI.On January 8, 2026, the Company announced positive tissue health data from its ongoing RESOLVE trial in EoE demonstrating near-complete improvement on biopsy. On February 20, 2026, the Company announced the closing of a public offering of Common Shares (the “Offering”). The Company issued 7,607,145 Common Shares at a price of $7.00 per Common Share for gross proceeds of approximately $63.2 million which included the issuance of 1,178,571 Common Shares upon full exercise of the option to purchase additional shares granted to the underwriters, and 1,428,571 Pre-Funded Warrants at a price of $6.99999 per Pre-Funded Warrant.
Fourth Quarter 2025 Financial Review

The Company incurred a net loss of $16.7 million for the three months ended December 31st, 2025, versus a net loss of $7.5 million for the three months ended December 31st, 2024. The increase in net loss was primarily due to an increase in research and development costs associated with the EP-104GI program and increased general and administrative costs.

The Company had cash of $80.5 million as of December 31st, 2025, up from $33.1 million at the end of the fourth quarter of 2024.

The Company anticipates that existing cash reserves and proceeds from the Offering and anticipated future exercise of in-the-money warrants, will be sufficient to fund the Company into the second half of 2028.

As of December 31st 2025, the Company had 51,939,206 common shares and 8,355,638 preferred shares outstanding.

Potential Impact of Tariffs

Management continues to monitor the North American trade situation that began with the February 2025 announcement by the U.S. government of proposed 25% tariffs on selected imported Canadian goods, and the subsequent Canadian announcement of planned retaliatory tariffs on selected imported U.S. goods. At present, U.S. tariffs are in flux following the recent U.S. Supreme Court decision regarding the scope of executive tariff authority that struck down certain tariffs that had been in place.

Eupraxia manufactures its clinical supplies of EP-104IAR and EP-104GI in the U.S. by a third-party. The Company expects to continue to access manufactured products from the U.S.

The Company maintains U.S. dollar balances to pay U.S. dollar expenses and to minimize the impact of short-term fluctuations in exchange rates.

Management continues to assess the potential direct and indirect impacts of tariffs, counter-tariffs and other trade protection measures on Eupraxia's business and will take those steps it deems necessary to attempt to mitigate any impact as the situation evolves.

Financial Statements and Management Discussion & Analysis

Please see the audited consolidated financial statements and related MD&A for more details. The audited consolidated financial statements for the year ended December 31, 2025, and related MD&A have been reviewed and approved by Eupraxia's Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed under the Company's profile on EDGAR at www.sec.gov and on SEDAR+ at sedarplus.ca and which is also available on the Company's website at www.eupraxiapharma.com.

About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.

Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Company’s next phase of growth; the expected cash runway to fund pipeline development and operations into the second half of 2028; the use of proceeds from the Offering; the anticipated proceeds from future exercise of in-the-money warrants; the Company’s expectation that it will continue to access manufactured products from the U.S.; the potential imposition of a new reciprocal tariff rate; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company’s product candidates; the results gathered from studies and trials of Eupraxia's product candidates and the timing of the release thereof; the potential for the Company’s technology to impact the drug delivery process; potential market opportunity for the Company’s product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:
James Meikle, Eupraxia Pharmaceuticals Inc.
236.330.7084
[email protected]

or

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
[email protected]

SOURCE Eupraxia Pharmaceuticals Inc.

SentinelOne, Inc. (S) Q4 2026 Earnings Call March 12, 2026 4:30 PM EDT

Company Participants

Saad Nazir
Tomer Weingarten - Co-Founder, Chairman, President & CEO
Barry Padgett - Interim CFO & Chief Growth Officer

Conference Call Participants

Brian Essex - JPMorgan Chase & Co, Research Division
John DiFucci - Guggenheim Securities, LLC, Research Division
Meta Marshall - Morgan Stanley, Research Division
Nasr Islam - Deutsche Bank AG, Research Division
Shrenik Kothari - Robert W. Baird & Co. Incorporated, Research Division
Patrick Edwin Colville - Scotiabank Global Banking and Markets, Research Division
Richard Poland - Wells Fargo Securities, LLC, Research Division
Michael Cikos - Needham & Company, LLC, Research Division
Shaul Eyal - TD Cowen, Research Division
Roger Boyd - UBS Investment Bank, Research Division
Joseph Gallo - Jefferies LLC, Research Division
Eric Heath - KeyBanc Capital Markets Inc., Research Division
Adam Tindle - Raymond James & Associates, Inc., Research Division
Jonathan Ho - William Blair & Company L.L.C., Research Division
Ittai Kidron - Oppenheimer & Co. Inc., Research Division

Presentation

Operator

Hello, and welcome to the SentinelOne Q4 FY 2026 Earnings Conference Call.

[Operator Instructions]

Also, as a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. I will now turn the call over to Saad Nazir, Head of Investor Relations.

Saad Nazir

Good afternoon, everyone, and welcome to SentinelOne's earnings call for the fiscal year ended January 31, 2026. With us today are Tomer Weingarten, CEO; and Barry Padgett, Interim CFO.

Our press release and an earnings presentation were issued earlier today and are posted on the Investor Relations section of our website. This call and accompanying slides are being broadcast live via webcast, and a replay will be available on our website after the call.

Before we begin, I would like to remind you that during today's call, we'll be making forward-looking statements about financial

Oil prices edged lower in Asia on a likely technical correction.

5.02K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of SCHD, DGRW either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call March 12, 2026 4:30 PM EDT

Company Participants

Leiv Lea - Chief Financial Officer
Richard Miller - Co-Founder, President, CEO & Chairman of the Board

Conference Call Participants

Zack Kubow - Real Chemistry, Inc.
Jiale Song - Jefferies LLC, Research Division
Li Wang Watsek - Cantor Fitzgerald & Co., Research Division
Graig Suvannavejh - Mizuho Securities USA LLC, Research Division
Jeffrey Jones - Oppenheimer & Co. Inc., Research Division
Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division
Xun Lee - H.C. Wainwright & Co, LLC, Research Division

Presentation

Operator

Good afternoon, everyone, and thank you for standing by, and welcome to the Corvus Pharmaceuticals Fourth Quarter and Full Year 2025 Business Update and Financial Results Conference Call. [Operator Instructions]

It is now my pleasure to turn the call over to Mr. Zack Kubow from Real Chemistry. Please go ahead, sir.

Zack Kubow
Real Chemistry, Inc.

Thank you, operator, and good afternoon, everyone. Thanks for joining us for the Corvus Pharmaceuticals Fourth Quarter and Full Year 2025 Business Update and Financial Results Conference Call. On the call to discuss the results and business updates are Richard Miller, Chief Executive Officer; Leiv Lea, Chief Financial Officer; Jeff Arcara, Chief Business Officer; and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences.

The executive team will open the call with some prepared remarks followed by a question-and-answer period. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in Corvus' annual report on Form 10-K for the year ended December 31, 2025, and

SummaryCompaniesRippling raises $450 million, plans $200 million employee equity repurchaseRippling fetches higher valuation amid tariffs uncertaintyCEO: No immediate IPO plans, profitability needed firstMay 9 (Reuters) - HR software startup Rippling said on Friday it raised $450 million in a Series G funding round, valuing the company at $16.8 billion, as it expands its workforce management products and focuses on growing revenue globally over profitability.

Y Combinator, Elad Gil, Sands Capital, GIC and Goldman Sachs Growth, along with other existing investors, participated in the round. In addition to the primary financing, the San Francisco-based startup also plans to repurchase up to $200 million of equity from current and former employees through a tender offer.

Learn about the latest breakthroughs in AI and tech with the Reuters Artificial Intelligencer newsletter. Sign up here.

Rippling's CEO Praker Conrad said the tender offer is likely to be an annual event, joining a growing list of high-profile private companies that don't want to go public yet but still want to offer ways for employees and early investors to cash out.

"I think the company would really need to be profitable before we go public," Conrad said in an interview. "We don't have any specific plans to go public. But I think we're at a scale where we want to try to create liquidity opportunities for employees and for investors."

This round, which values the company higher than its previous valuation of $13.5 billion in early 2024, faced an unexpected challenge due to its timing, as it was launched weeks before President Trump's tariff announcement, which has caused major volatility in the stock market. It also came amid ongoing legal disputes with competitor Deel, in which Deel was accused of corporate espionage.

Rippling, while not profitable, said it has well surpassed $100 million in annual recurring revenue and now serves over 20,000 customers with its expanding suite of more than 20 products spanning HR, IT and finance management, and plans to use the proceeds to invest in the core products.

"We're fortunate that we're still growing at a pretty fast pace. For us, the trade-off is always like, well, we could be profitable if we grew more slowly. And right now, the decision is that we want to keep growing," said Conrad.

Founded in 2016, Rippling's platform integrates workforce management services including payroll, benefits and corporate card services. International expansion has been a key driver of growth for the company amid increasing demand for HR solutions that can manage distributed workforces across multiple countries.

Rippling recently filed a lawsuit against Deel, alleging corporate espionage and other improper business practices. A former Rippling employee confessed to spying for Deel Inc, according to an affidavit made public in an Irish court in April.

The litigation has drawn attention to competitive practices and raised questions about ethical standards in the tech industry.

Reporting by Krystal Hu in New York; Editing by Susan Fenton

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Krystal reports on venture capital and startups for Reuters. She covers Silicon Valley and beyond through the lens of money and characters, with a focus on growth-stage startups, tech investments and AI. She has previously covered M&A for Reuters, breaking stories on Trump's SPAC and Elon Musk's Twitter financing. Previously, she reported on Amazon for Yahoo Finance, and her investigation of the company's retail practice was cited by lawmakers in Congress. Krystal started a career in journalism by writing about tech and politics in China. She has a master's degree from New York University, and enjoys a scoop of Matcha ice cream as much as getting a scoop at work.

Shimmick Corporation (SHIM) Q4 2025 Earnings Call Transcript

Solid Biosciences Inc. (SLDB) Barclays 28th Annual Global Healthcare Conference March 12, 2026 11:30 AM EDT

Company Participants

Alexander Cumbo - President, CEO & Director
Gabriel Brooks - Chief Medical Officer

Conference Call Participants

Eliana Merle - Barclays Bank PLC, Research Division
Tejas Wein - Barclays Bank PLC, Research Division

Presentation

Eliana Merle
Barclays Bank PLC, Research Division

Hi, guys. Good afternoon. I'm Ellie Merle, one of the biotech analysts here at Barclays. Joining me from Barclays is my colleague, Tejas Wein. We're very happy to have Solid Biosciences here with us today. A lot to talk about after a data update yesterday. Joining us from Solid is Bo Cumbo, President and Chief Executive Officer; and Gabriel Brooks, Chief Medical Officer. Thank you both so much for making the time.

Question-and-Answer Session

Eliana Merle
Barclays Bank PLC, Research Division

Maybe to begin, can you give an overview of your program and where you see it in the DMD landscape?

Alexander Cumbo
President, CEO & Director

Yes. First, thank you very much for the invitation. Thank you, Ellie. Yes, Solid is a precision genetic medicine company. We focus on our lead programs, Duchenne muscular dystrophy called 003, followed by a Friedreich's ataxia program. We also have multiple cardiac programs, CPVT, TNNT2. And we make a host of delivery technologies such as capsids, promoters, dual plasmids for gene therapy delivery as well. And do you want to go in the DMD program?

Eliana Merle
Barclays Bank PLC, Research Division

Yes. Yes, let's go for it. I mean, there's a bunch of DMD gene therapy programs. So, let's talk through your program and how you think it compares to the others.

Alexander Cumbo
President, CEO & Director

Yes. Obviously, they're not head-to-head comparison trials going on. But I think 003 is really one of the most comprehensive

Q3: 2026-03-12 Earnings SummaryEPS of -$1.53 misses by $1.27

 |

Revenue of

$286.79M

(-11.95% Y/Y)

misses by $42.47M

America's Car-Mart, Inc. (CRMT) Q3 2026 Earnings Call March 12, 2026 9:00 AM EDT

Company Participants

Jonathan Collins - Chief Financial Officer
Douglas Campbell - CEO, President & Director
Jamie Fischer - Chief Operating Officer

Conference Call Participants

John Hecht - Jefferies LLC, Research Division
Kyle Joseph - Stephens Inc., Research Division
Vincent Caintic - BTIG, LLC, Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to the America's Car-Mart Third Quarter Fiscal 2026 Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Jonathan Collins, Chief Financial Officer. Please go ahead.

Jonathan Collins
Chief Financial Officer

Good morning. I'm Jonathan Collins, the company's Chief Financial Officer. Welcome to America's Car-Mart's Third Quarter Fiscal Year 2026 Earnings Call for the period ended January 31, 2026. Joining me on the call today is Doug Campbell, our President and CEO; and Jamie Fischer, our COO. We issued our earnings release earlier this morning, and a supplemental presentation is available on our website. We will post the transcript of our prepared remarks following this call, and the Q&A session will be available through the webcast.

During today's call, certain statements we make may be considered forward-looking and inherently involve risks and uncertainties that could cause actual results to differ materially from management's present view. These statements are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. The company cannot guarantee the accuracy of any forecast or estimate nor does it undertake any obligation to update such forward-looking statements.

For more information, including important cautionary notes, please see Part 1 of the company's annual report on Form 10-K for the fiscal year ended April 30, 2025, and our current and quarterly